Walk me through the covenant compliance certificate process and why the credit agreement's EBITDA definition matters so much.
A core Corporate Treasury interview question — asked in analyst and associate interviews across IB, PE, and the Big 4.
THE SHORT ANSWER
Periodically (usually quarterly) the borrower delivers a compliance certificate to lenders certifying the financial covenants — typically leverage, interest cover, sometimes capex — with the supporting calculation. The make-or-break detail is that you must use the credit agreement's defined 'EBITDA', not reported EBITDA: the definition specifies permitted add-backs (one-offs, restructuring costs, run-rate/pro-forma synergies, sometimes uncapped) and adjustments, so 'covenant EBITDA' can differ materially from statutory EBITDA. Treasury models headroom on that defined basis, watches the permitted add-back caps, and forecasts forward to flag a potential breach early. Getting the definition wrong — or assuming reported numbers — can mean falsely certifying compliance or missing an approaching breach, both serious. So the credit agreement definitions, not the accounts, govern.
WHAT INTERVIEWERS LISTEN FOR
- ✓Periodic certificate certifying covenants with calculations
- ✓Use the agreement's defined EBITDA, not reported
- ✓Add-backs/adjustments defined and sometimes capped
- ✓Forecast headroom forward to flag breaches early
COMMON MISTAKES
- ✗Using statutory EBITDA for covenants
- ✗Ignoring defined add-back caps
- ✗No forward-looking breach monitoring
Reading isn't the same as answering under pressure.
Interviewers don't hand you the model answer — you deliver yours on a clock. Practice this and 1,000+ questions with AI feedback on every answer.
RELATED QUESTIONS
- How do you prepare for a rating agency meeting?
- A company has a €500M bond maturing in 2 years and a €300M RCF undrawn. The CFO wants to refinance now to lock in low rates. You notice the RCF has a material adverse change (MAC) clause. How does this affect your refinancing strategy?
- A company has a €200M RCF with a net leverage covenant of 3.5x. After a large acquisition, net debt/EBITDA is 3.8x. You have a cure right to inject equity. The CFO asks: should we cure now or wait? What factors drive your decision?
- Why do rating agencies and investors expect a commercial paper program to be backed by committed bank lines, and how much backup is appropriate?
- Why can supply-chain finance (reverse factoring) be reclassified from trade payables to debt, and why do investors and rating agencies care?
- What is a make-whole call provision, and how does it affect the economics of redeeming a bond early?